AriBio is a clinical-stage biotech company located in Seongnam, South Korea focused on developing novel therapeutics for neurodegenerative diseases. The US office is located in San Diego managing global clinical operations and regulatory affairs. The lead asset, AR1001, is entering a global phase 3 program this year.
Founded date: 2010
Investors 1
| Date | Name | Website |
| - | KTB Networ... | ktbnetwork... |
Mentions in press and media 4
| Date | Title | Description |
| 19.10.2024 | Revolutionizing Alzheimer's Diagnosis: The Neurophet and AriBio Collaboration | In the realm of Alzheimer's disease, innovation is the lifeblood of hope. Neurophet, a South Korean AI company, is at the forefront of this revolution. Their recent partnership with AriBio, a biopharmaceutical firm, aims to reshape how we d... |
| 15.10.2024 | Neurophet-AriBio to develop 'Next-Gen Platform for Alzheimer's diagnosis' | - Neurophet's brain MRI analysis technology incorporates fluid biomarker data from AriBio's global Phase 3 clinical trial for Alzheimer's disease - Collaborates leveraging Neurophet's medical image analysis technology and AriBio's clinical ... |
| 04.10.2024 | Indian mental health app Lissun takes on AI with $3M and more briefs | Photo: Pixabay/Pexels Mental health app Lissun bags $3M for AI integration Mental health platform Lissun in India has scored $2.5 million in a pre-Series A funding round led by RPSG Capital Ventures. With its fresh funds, the startup plans ... |
| 31.05.2024 | Neurophet to participate BIO USA… exploring global partnership and business | Neurophet's AI brain image analysis technology improves time and cost efficiency for drug development Aims to create business opportunities with global pharmaceutical companies SEOUL, South Korea, May 31, 2024 /PRNewswire/ -- Neurophet, an ... |